NEW YORK (GenomeWeb) – Fluidigm's second quarter revenues jumped 58 percent year over year, or 32 percent organically, the company reported after the close of the market on Thursday.

For the three months ended June 30, Fluidigm's total revenues increased to $27.6 million from $17.5 million in the year-ago quarter and beat the consensus analysts' estimate of $27.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.